FDA approved Tagrisso (osimertinib) in the U.S. for treatment of adult patients with unresectable, stage 3 epidermal growth factor receptor-mutated non-small cell lung cancer whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
